Literature DB >> 31656296

The risk of hemorrhage in stereotactic biopsy for brain tumors.

Yoshifumi Mizobuchi1, Kohei Nakajima1, Toshitaka Fujihara1, Kazuhito Matsuzaki2, Hideo Mure1, Shinji Nagahiro1, Yasushi Takagi1.   

Abstract

Objective : One major complication associated with STB is intratumoral hematoma, which is also the most common cause of morbidity related to permanent paralysis and mortality in STB. The risk of perioperative hemorrhage is generally between 1% and 10%, but this could be an underestimation since it is not common for many neurosurgeons to perform CT scans after uncomplicated STBs. In this study, we describe the incidence of cerebral hemorrhage, including asymptomatic cerebral hemorrhage. Methods : We recently reviewed data on the diagnosis rate and occurrence of complications, including symptomatic and asymptomatic cerebral hemorrhage, in 80 patients who underwent STB at our facility between 2005 and 2014. Results : Histological diagnosis was established for 75 cases (93.8%), glioma was the most frequently encountered tumor. Symptomatic hemorrhage was observed in two cases (2.6%), with the symptoms subsiding within two days. The morbidity and mortality rate was 0%. However, asymptomatic hemorrhages were observed in 23 cases (28.8%). Conclusion : Stereotactic biopsy is a less invasive procedure for obtaining samples of brain tumors for diagnosis. The bleeding of the tissue-resection cavity that includes asymptomatic hemorrhage occurs at a constant rate. It is important to reduce the symptomatic bleeding associated with stereotactic biopsy. J. Med. Invest. 66 : 314-318, August, 2019.

Entities:  

Keywords:  intratumoral hematoma; silent hemorrhage; stereotactic biopsy

Mesh:

Year:  2019        PMID: 31656296     DOI: 10.2152/jmi.66.314

Source DB:  PubMed          Journal:  J Med Invest        ISSN: 1343-1420


  6 in total

1.  The Real-World status and risk factors for a poor prognosis in elderly patients with primary central nervous system malignant lymphomas: a multicenter, retrospective cohort study of the Tohoku Brain Tumor Study Group.

Authors:  Kenichiro Asano; Yoji Yamashita; Takahiro Ono; Manabu Natsumeda; Takaaki Beppu; Kenichiro Matsuda; Masahiro Ichikawa; Masayuki Kanamori; Masashi Matsuzaka; Akira Kurose; Kiyoshi Saito; Yukihiko Sonoda; Kuniaki Ogasawara; Yukihiko Fujii; Hiroaki Shimizu; Hiroki Ohkuma; Chifumi Kitanaka; Takamasa Kayama; Teiji Tominaga
Journal:  Int J Clin Oncol       Date:  2021-10-12       Impact factor: 3.402

2.  Indicators of correct targeting in stereotactic biopsy of intracranial lesions.

Authors:  Osvaldo Vilela-Filho; Jairo Porfírio; Lissa C Goulart
Journal:  Surg Neurol Int       Date:  2022-06-17

3.  Electroporation-based proteome sampling ex vivo enables the detection of brain melanoma protein signatures in a location proximate to visible tumor margins.

Authors:  Ilai Genish; Batel Gabay; Angela Ruban; Yona Goldshmit; Amrita Singh; Julia Wise; Klimentiy Levkov; Avshalom Shalom; Edward Vitkin; Zohar Yakhini; Alexander Golberg
Journal:  PLoS One       Date:  2022-05-19       Impact factor: 3.752

4.  Case Report: Clinical Use of a Patient-Individual Magnetic Resonance Imaging-Based Stereotactic Navigation Device for Brain Biopsies in Three Dogs.

Authors:  Sarah Gutmann; Thomas Flegel; Marcel Müller; Robert Möbius; Kaspar Matiasek; Florian König; Dirk Winkler; Ronny Grunert
Journal:  Front Vet Sci       Date:  2022-07-14

5.  A Comparation Between Frame-Based and Robot-Assisted in Stereotactic Biopsy.

Authors:  Yue Hu; Pu Cai; Huawei Zhang; Aihemaitiniyazi Adilijiang; Jun Peng; Yun Li; Shanli Che; Fei Lan; Changqing Liu
Journal:  Front Neurol       Date:  2022-07-18       Impact factor: 4.086

6.  High Precision Bone Cutting by Er: YAG Lasers Might Minimize the Invasiveness of Navigated Brain Biopsies.

Authors:  Thanh Tu Ha; Florian M Thieringer; Martin Bammerlin; Dominik Cordier
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.